J
Junna Oba
Researcher at University of Texas MD Anderson Cancer Center
Publications - 31
Citations - 1748
Junna Oba is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 13, co-authored 28 publications receiving 1174 citations. Previous affiliations of Junna Oba include Kyushu University & Keio University.
Papers
More filters
Journal ArticleDOI
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
A. Gordon Robertson,Juliann Shih,Juliann Shih,Christina Yau,Ewan A. Gibb,Junna Oba,Karen Mungall,Julian M. Hess,Vladislav Uzunangelov,Vonn Walter,Vonn Walter,Ludmila Danilova,Tara M. Lichtenberg,Melanie H. Kucherlapati,Patrick K. Kimes,Ming Tang,Alexander V Penson,Özgün Babur,Rehan Akbani,Christopher A. Bristow,Katherine A. Hoadley,Lisa Iype,Matthew T. Chang,Matthew T. Chang,Mohamed H. Abdel-Rahman,Adrian Ally,J. Todd Auman,Miruna Balasundaram,Saianand Balu,Christopher C. Benz,Rameen Beroukhim,Inanc Birol,Tom Bodenheimer,Jay Bowen,Reanne Bowlby,Denise Brooks,Rebecca Carlsen,Colleen M. Cebulla,Andrew D. Cherniack,Andrew D. Cherniack,Lynda Chin,Juok Cho,Eric Chuah,Sudha Chudamani,Carrie Cibulskis,Kristian Cibulskis,Leslie Cope,Sarah E. Coupland,Timothy Defreitas,John A. Demchok,Laurence Desjardins,Noreen Dhalla,Bita Esmaeli,Ina Felau,Martin L. Ferguson,Scott Frazer,Stacey Gabriel,Julie M. Gastier-Foster,Nils Gehlenborg,Mark Gerken,Jeffrey E. Gershenwald,Gad Getz,Klaus G. Griewank,Elizabeth A. Grimm,D. Neil Hayes,Apurva M. Hegde,David I. Heiman,Carmen Helsel,Shital Hobensack,Robert A. Holt,Alan P. Hoyle,Xin Hu,Carolyn M. Hutter,Martine J. Jager,Stuart R. Jefferys,Corbin D. Jones,Steven J.M. Jones,Cyriac Kandoth,Katayoon Kasaian,Jaegil Kim,Raju Kucherlapati,Eric S. Lander,Michael S. Lawrence,Alexander J. Lazar,Semin Lee,Kristen M. Leraas,Pei Lin,Jia Liu,Wen-Bin Liu,Laxmi Lolla,Yiling Lu,Yussanne Ma,Harshad S. Mahadeshwar,Odette Mariani,Marco A. Marra,Michael Mayo,Sam Meier,Shaowu Meng,Matthew Meyerson,Piotr A. Mieczkowski,Gordon B. Mills,Richard A. Moore,Lisle E. Mose,Andrew J. Mungall,Bradley A. Murray,Rashi Naresh,Michael S. Noble,Angeliki Pantazi,Michael Parfenov,Peter J. Park,Joel S. Parker,Charles M. Perou,Todd Pihl,Robert Pilarski,Alexei Protopopov,Amie Radenbaugh,Karan Rai,Nilsa C. Ramirez,Xiaojia Ren,Sheila Reynolds,Jeffrey Roach,Sergio Roman-Roman,Jason Roszik,Sara Sadeghi,Gordon Saksena,Xavier Sastre,Dirk Schadendorf,Jacqueline E. Schein,Lynn Schoenfield,Steven E. Schumacher,Jonathan G. Seidman,Sahil Seth,Geetika Sethi,Margi Sheth,Yan Shi,Carol L. Shields,Ilya Shmulevich,Janae V. Simons,Arun D. Singh,Payal Sipahimalani,Tara Skelly,Heidi J. Sofia,Matthew G. Soloway,Xingzhi Song,Marc-Henri Stern,Joshua M. Stuart,Qiang Sun,Huandong Sun,Angela Tam,Donghui Tan,Jiabin Tang,Roy Tarnuzzer,Barry S. Taylor,Nina Thiessen,Vesteinn Thorsson,Kane Tse,Umadevi Veluvolu,Roel G.W. Verhaak,Doug Voet,Yunhu Wan,Zhining Wang,John N. Weinstein,Matthew D. Wilkerson,Michelle D. Williams,Lisa Wise,Scott E. Woodman,Tina Wong,Ye Wu,Liming Yang,Lixing Yang,Jean C. Zenklusen,Jiashan Zhang,Hailei Zhang,Erik Zmuda +173 more
TL;DR: Within D3-UM, EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number alterations and DNA methylation profiles, providing insight into the biology of these low- versus intermediate-risk clinical mutation subtypes.
Journal ArticleDOI
CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-l1 blockade
Limo Chen,Lixia Diao,Yongbin Yang,Xiaohui Yi,B. Leticia Rodriguez,Y. Li,Y. Li,Pamela Villalobos,Tina Cascone,Xi Liu,Lin Tan,Philip L. Lorenzi,Anfei Huang,Qiang Zhao,Di Peng,Jared J. Fradette,David H. Peng,Christin Ungewiss,Jonathon D. Roybal,Pan Tong,Junna Oba,Ferdinandos Skoulidis,Weiyi Peng,Brett W. Carter,Youhong Fan,Caleb A. Class,Jingfen Zhu,Jaime Rodriguez-Canales,Masanori Kawakami,Lauren Averett Byers,Scott E. Woodman,Vassiliki A. Papadimitrakopoulou,Ethan Dmitrovsky,Jing Wang,Stephen E. Ullrich,Ignacio I. Wistuba,John V. Heymach,F. Xiao Feng Qin,F. Xiao Feng Qin,Don L. Gibbons +39 more
TL;DR: It is observed that tumors treated with PD-1/PD-L1 blocking antibodies develop resistance through the upregulation of CD38, which is induced by all-trans retinoic acid and IFNβ in the tumor microenvironment, providing a novel mechanism of acquired resistance to immune checkpoint therapy.
Journal ArticleDOI
Uveal Melanoma: From Diagnosis to Treatment and the Science in Between
Chandrani Chattopadhyay,Dae Won Kim,Dan S. Gombos,Junna Oba,Yong Qin,Michelle D. Williams,Bita Esmaeli,Elizabeth A. Grimm,Jennifer A. Wargo,Scott E. Woodman,Sapna Pradyuman Patel +10 more
TL;DR: Clinical trials directed at uveal melanoma have been completed or are in progress, and data from these well designed investigations will help guide future directions in this orphan disease.
Journal ArticleDOI
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma (vol 32, pg 204, 2017)
A.G. Robertson,Juliann Shih,Christina Yau,Ewan A. Gibb,Junna Oba,K. Mungall,Julian M. Hess,Vladislav Uzunangelov,Vonn Walter,Ludmila Danilova,Tara M. Lichtenberg,Melanie H. Kucherlapati,Patrick K. Kimes,Ming Tang,Alexander V Penson,Özgün Babur,Rehan Akbani,Christopher A. Bristow,Katherine A. Hoadley,Lisa Iype,Matthew T. Chang,Andrew D. Cherniack,Christopher C. Benz,Gordon B. Mills,Roeland Verhaak,Klaus G. Griewank,Ina Felau,Jean C. Zenklusen,Jeffrey E. Gershenwald,Lynn Schoenfield,Alexander J. Lazar,Mohamed H. Abdel-Rahman,Sergio Roman-Roman,Marc-Henri Stern,Colleen M. Cebulla,Williams,Martine J. Jager,Sarah E. Coupland,Bita Esmaeli,Cyriac Kandoth,Scott E. Woodman +40 more
TL;DR: In this paper, a multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better prognosis disomy 3(D3), which correlates with a global DNA methylation state that is distinct from D3-UM.
Journal ArticleDOI
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
Jason Roszik,Lauren E. Haydu,Kenneth R. Hess,Junna Oba,Aron Y. Joon,Alan E. Siroy,Tatiana Karpinets,Francesco C. Stingo,Veerabhadran Baladandayuthapani,Michael T. Tetzlaff,Jennifer A. Wargo,Ken Chen,Marie Andrée Forget,Cara Haymaker,Jie Qing Chen,Funda Meric-Bernstam,Agda Karina Eterovic,Kenna R. Shaw,Gordon B. Mills,Jeffrey E. Gershenwald,Laszlo Radvanyi,Patrick Hwu,P. Andrew Futreal,Don L. Gibbons,Alexander J. Lazar,Chantale Bernatchez,Michael A. Davies,Scott E. Woodman +27 more
TL;DR: The approach of using small NGS gene panels, already applied to guide employment of targeted therapies, may have utility in the personalized use of immunotherapy in cancer.